In patients with systolic HF addressed for persistent AF ablation, higher baseline galectin-3 levels identify non-responders to ablation, i.e. patients with a higher risk of arrhythmia recurrence, a lower chance of recovery after ablation (without AIC), and a higher risk of subsequent HF hospitalization and/or cardiac death. The gene discussed is LGALS3; the disease is Arrhythmia.